News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cytokinetics, Inc. (CYTK) Amends ALS Therapy Trial Design After Mistake


7/23/2013 7:32:35 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cytokinetics Inc. (CYTK:US), the developer of an experimental drug for amyotrophic lateral sclerosis, said it will increase the number of patients in a trial of the therapy after some were given a placebo by mistake. After talking with regulators, Cytokinetics expanded the trial to include about 680 patients and updated the statistical methods section. The changes are expected to increase trial costs by about $5 million this year and next, the South San Francisco, California-based company said today in a statement.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES